MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma

NCT03489525 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

107

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

BIOLOGICAL: Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
BIOLOGICAL: Dose Expansion, MEDI2228, ADC (antibody drug conjugate)

Sponsor

MedImmune LLC